Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Current Deferred Revenue (2016 - 2018)

Heron Therapeutics (HRTX) has disclosed Current Deferred Revenue for 4 consecutive years, with $14.0 million as the latest value for Q4 2018.

  • For the quarter ending Q4 2018, Current Deferred Revenue changed N/A year-over-year to $14.0 million, compared with a TTM value of $14.0 million through Dec 2018, changed N/A, and an annual FY2018 reading of $14.0 million, changed N/A over the prior year.
  • Current Deferred Revenue was $14.0 million for Q4 2018 at Heron Therapeutics, up from $10.5 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $14.0 million in Q4 2018 and bottomed at $1.1 million in Q4 2016.
  • Average Current Deferred Revenue over 3 years is $6.6 million, with a median of $5.4 million recorded in 2017.
  • Peak annual rise in Current Deferred Revenue hit 97.2% in 2018, while the deepest fall reached 55.21% in 2018.
  • Year by year, Current Deferred Revenue stood at $1.1 million in 2016, then surged by 405.91% to $5.6 million in 2017, then skyrocketed by 151.98% to $14.0 million in 2018.
  • Business Quant data shows Current Deferred Revenue for HRTX at $14.0 million in Q4 2018, $10.5 million in Q3 2018, and $9.4 million in Q2 2018.